Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana…·Enrique Santamaría
The paper uses proteomic analysis of the olfactory tract to identify pyroxamide, an HDAC1 inhibitor, as a potential therapeutic for Parkinson's disease by reducing α-synuclein fibril-induced toxicity in cell lines.